Translational mini-review series on complement factor H: genetics and disease associations of human complement factor
S Rodríguez de Córdoba1, E Goicoechea de Jorge
1Centro de Investigaciones Biológicas and Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain. SRdeCordoba@cib.csic.es
Clinical and Experimental Immunology
|December 18, 2007
Summary
Complement factor H (CFH) genetic variations are linked to serious diseases like aHUS, AMD, and MPGN. Understanding CFH genotype-phenotype correlations is key to deciphering the molecular basis of these conditions.
Area of Science:
- Immunology
- Genetics
- Nephrology
- Ophthalmology
Background:
- Factor H is a key regulator of the complement system, protecting host cells from damage.
- Genetic variations in the complement factor H gene (CFH) are associated with several pathologies.
- Atypical haemolytic uraemic syndrome (aHUS), age-related macular degeneration (AMD), and membranoproliferative glomerulonephritis (MPGN) are linked to CFH variations.
Purpose of the Study:
- To review current knowledge of CFH genetics.
- To examine genotype-phenotype correlations in CFH.
- To elucidate the molecular basis of aHUS, AMD, and MPGN.
Main Methods:
- Literature review of recent studies on CFH genetics.
- Analysis of genotype-phenotype correlations.
- Synthesis of information on renal and ocular pathologies associated with CFH.
Main Results:
- CFH genetic variations are significantly associated with aHUS, AMD, and MPGN.
- Specific CFH genotypes correlate with distinct clinical presentations (phenotypes).
- These correlations provide insights into the molecular mechanisms of these diseases.
Conclusions:
- CFH genetics plays a crucial role in the pathogenesis of aHUS, AMD, and MPGN.
- Understanding genotype-phenotype relationships is essential for diagnosing and potentially treating these conditions.
- Further research into CFH function and variation will advance our knowledge of complement-mediated diseases.
Related Concept Videos
01:31Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
01:31Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:43Incomplete Dominance
Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...